Please Scroll Down to See Forums Below 
especially when taking winnie, primo, and other drugs like dbol?
Winnie and Primo is suppossed to be the shit together....by DHT may be a problem..seeing as both basically eat your heads hair...........would this help??????????????
PROPECIA (ORAL FINASTERIDE) IN THE TREATMENT OF ALOPECIA ANDROGENETICA & INSTRUCTIONS FOR USE
Reduces 66% + - of DHT in blood serum
(Click on Azelaic Acid for purposes of comparison)
--------------------------------------------------------------------------------
FINASTERIDE
There is no doubt that androgens are intimately involved in causing male pattern baldness. Famous castrati in the time of Handel and Teleman not only retained strong soprano voices, but were assured of a lifetime of beautiful locks. Hamilton, known popularly for the Hamilton Scale of grading male pattern baldness, noted that castration after the onset of puberty arrests the progression of human alopecia (1). On the other hand, the administration of therapeutic doses of testosterone to hypogonadal adult males results in the loss of scalp hair (whereas there is no noticeable change in the scalp hair of normal men).
The active androgen in the balding scalp appears to be dihydrotestosterone, which is produced from testosterone through the activity of the 5-alpha-reductase enzyme (2). Biopsies and biochemical analyses corroborate the elevated 5-alpha-reductase levels in the frontal scalp of balding men and the lack of hair loss in human males with 5-alpha-reductase deficiencies.(3) In fact, the levels of 5-alpha-reductase is usually 4 times higher in balding areas than the occiput, which is not affected in male pattern baldness.
Recently, two isoenzymes of 5-alpha-reductase have been identified in human tissue. The type 1 isoenzyme is found in scalp skin, whereas 5-alpha-reductase of type 2 is the predominant form in the prostate (4).Propecia, also known as 1 mg. finasteride, is a potent inhibitor of human 5-alpha-reductase, yet devoid of antiandrogen activity (5) itself, so the circulating levels of testosterone are not affected.
Finasteride, manufactured and marketed by Merck Pharmaceutical as Proscar, has been shown to be effective in the treatment of benign prostatic hyperplasia. At the therapeutic dose of 5 mg/day, finasteride lowers serum dihydrotestosterone levels in men by 65-80% compared to baseline levels and decreases intraprostatic levels of dihydrotestosterone by 85% compared to placebo (6). Finasteride has been approved for use in treatment of BPH since 1994. In January of 1998 the FDA in the U.S.A. approved Propecia, a 1 mg. tablet of finasteride by Merck for the treatment of alopecia androgenetica.
Since the pathogenesis of balding in the stumptail macaque monkey and human appears to be similar and partially reversible in both species by long term use of topical minoxidil solutions, clinical trials were performed in 1991 in these primates to evaluate the hair growth effects of oral administration of finasteride alone and in combination with topical minoxidil (7). The results showed that the combination of finasteride and minoxidil generated significant augmentation of hair weight (additive effect) compared to either drug alone. Furthermore, folliculograms of scalp biopsy tissue showed a higher frequency of late anagen follicles in subjects treated with 5% minoxidil than in those administered a 2% concentration (7). Analysis of the data confirms that using minoxidil and finasteride together is significantly better than using either alone, and that minoxidil in higher concentrations is more effective than at lower concentrations.
At the 1995 American Association of Dermatology Meeting in New Orleans, results from a one year, double-blind, randomized, placebo-controlled study with finasteride in the treatment of male pattern baldness were presented. Men taking oral finasteride (5 mg/day) had significantly increased hair counts and significantly improved clinical change from baseline as assessed by multiple parameters including patient self evaluation. There were few drug related side effects reported, with similar numbers in both finasteride and placebo groups.
At the same meeting, results from a dose-range-finding study were presented, evaluating finasteride at doses of 0.01, 0.05, 0.2, 1 and 5 mg/day. A six week trial measured concentrations of scalp skin and serum dihydrotestosterone. Surprisingly, other than the group taking 0.01 mg/day, no significant differences between the doses were seen. However, significant differences were documented between the groups that received finasteride (excluding those receiving 0.01 mg/day) and the group that received placebo. It was determined that a low dose of oral finasteride will be used for further studies in the treatment of male pattern baldness.
At the annual meeting of the American Academy of Dermatology during March, 1997 in San Francisco, the Phase III clinical trials were presented for Propecia, 1 mg. finasteride. The tests evaluated 1,553 men with male pattern baldness in placebo controlled studies for one year.
According to Keith Kaufman, M.D., director of clinical research at Merck & Co., Inc., there was a 107-hair improvement in men taking Propecia (1mg finasteride) compared to those receiving placebo. Scalp hair growth was measured by counting hairs in a 1 inch diameter circle of active hair loss at the vertex. The increased hair growth achieved with 1mg finasteride was evaluated by the patients as well as by clinical investigators and by review of patient photographs by a panel of dermatologists with expertise in hair loss. By all parameters, treatment with oral daily 1mg doses of finasteride demonstrated improved hair growth. Overall improvement was seen as early as three months with continued improvement over the 24 month trial.
The 1mg daily oral doses of finasteride were generally well tolerated as side effects were reportedly uncommon. Safety was evaluated in more than 3200 men through clinical and laboratory monitoring. Ironically, discontinuation of therapy in Phase III trials due to adverse experience occurred in a higher percentage in the men on placebo (2.1%) than in the men treated with Propecia (1.7%). According to Merck, less than 2% of men experienced decreased libido. Less than 1.5% of men had difficulty achieving an erection. And, less than 1% of men complained of a decrease in the amount of semen. According to Dr. Kaufman, these side effects resolved in men who discontinued therapy with Propecia and, in fact, in many who continued therapy with Propecia. It should be noted that this data was supplied by Merck & Co., not by REGROWTH, LLC.
The concentration of dihydrotestosterone in the scalp is decreased by approximately 60% in patients taking 1mg of finasteride daily. Since finasteride inhibits a key factor responsible for miniaturization of scalp hair follicles, this allows for a reversal of the balding process.
Subsequent reports from Merck & Co., Inc. demonstrate that daily doses of 1mg finasteride is also effective at halting hair loss. Evaluation at the end of a one year study showed that only 14% of patients on Propecia lost hair, as opposed to 58% of patients on placebo. There was continued improvement in patients taking 1 mg. finasteride over 24 months.
More recent results proved that finasteride is also successful in reversing frontal hair loss, although slightly less effectively than at the vertex. This additional information is very encouraging to many patients who are disappointed in the limited ability of minoxidil to stimulate frontal hair growth. The combination therapy has been effective for most patients.
When you are getting a physical examination or are having laboratory tests on your blood, inform your doctor that you are taking finasteride. Finasteride will decrease the PSA (Prostate Specific Antigen) level by approximately 50%. Assessing the PSA level is a screening test for possible prostate cancer.
Richard Lee, M.D.
(1)Hamilton JB. Male hormone stimulation is prerequisite and incitant in common baldness. Am J Anat. 71:451-80, 1942
(2)Ebling FJG. Hair follicles and associated glands as androgen targets. Clin Endocrinol Metab. 15:319-39, 1986
(3)Bingham KD, Shaw DA. The metabolism of testosterone by human male scalp skin. J Endocrinol. 57:111-21, 1973
(4)Jenkins, Anderson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steroid 5-alpha-reductase. J Clin Invest. 89:293-300, 1992
(5)Stoner E. The clinical development of a 5-alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 37:375-378, 1990
(6)Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1185-1191, 1992
(7)Diabi AR, Mulholland MJ, Shull KL, Kubicek MF, Johnson GA, Schostarez HJ, Brunden MN and Buhl AE. Hair Growth Effects of Oral Administration of finasteride, a steroid 5-alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab. 74:345-350, 1992
INSTRUCTIONS FOR USE:
Take one tablet by mouth each day
You may take Propecia with or without food
If you forget to take Propecia, do not take an extra tablet. Just take the next tablet as usual
Propecia will not work faster or better if you take it more than once a day or if you increase the dosage.
a couple of questions
1) would 1 mg a day be sufficient?
2) how long would you want to run it after cycle?
3) when would you want to start it?
thanks........
Winnie and Primo is suppossed to be the shit together....by DHT may be a problem..seeing as both basically eat your heads hair...........would this help??????????????
PROPECIA (ORAL FINASTERIDE) IN THE TREATMENT OF ALOPECIA ANDROGENETICA & INSTRUCTIONS FOR USE
Reduces 66% + - of DHT in blood serum
(Click on Azelaic Acid for purposes of comparison)
--------------------------------------------------------------------------------
FINASTERIDE
There is no doubt that androgens are intimately involved in causing male pattern baldness. Famous castrati in the time of Handel and Teleman not only retained strong soprano voices, but were assured of a lifetime of beautiful locks. Hamilton, known popularly for the Hamilton Scale of grading male pattern baldness, noted that castration after the onset of puberty arrests the progression of human alopecia (1). On the other hand, the administration of therapeutic doses of testosterone to hypogonadal adult males results in the loss of scalp hair (whereas there is no noticeable change in the scalp hair of normal men).
The active androgen in the balding scalp appears to be dihydrotestosterone, which is produced from testosterone through the activity of the 5-alpha-reductase enzyme (2). Biopsies and biochemical analyses corroborate the elevated 5-alpha-reductase levels in the frontal scalp of balding men and the lack of hair loss in human males with 5-alpha-reductase deficiencies.(3) In fact, the levels of 5-alpha-reductase is usually 4 times higher in balding areas than the occiput, which is not affected in male pattern baldness.
Recently, two isoenzymes of 5-alpha-reductase have been identified in human tissue. The type 1 isoenzyme is found in scalp skin, whereas 5-alpha-reductase of type 2 is the predominant form in the prostate (4).Propecia, also known as 1 mg. finasteride, is a potent inhibitor of human 5-alpha-reductase, yet devoid of antiandrogen activity (5) itself, so the circulating levels of testosterone are not affected.
Finasteride, manufactured and marketed by Merck Pharmaceutical as Proscar, has been shown to be effective in the treatment of benign prostatic hyperplasia. At the therapeutic dose of 5 mg/day, finasteride lowers serum dihydrotestosterone levels in men by 65-80% compared to baseline levels and decreases intraprostatic levels of dihydrotestosterone by 85% compared to placebo (6). Finasteride has been approved for use in treatment of BPH since 1994. In January of 1998 the FDA in the U.S.A. approved Propecia, a 1 mg. tablet of finasteride by Merck for the treatment of alopecia androgenetica.
Since the pathogenesis of balding in the stumptail macaque monkey and human appears to be similar and partially reversible in both species by long term use of topical minoxidil solutions, clinical trials were performed in 1991 in these primates to evaluate the hair growth effects of oral administration of finasteride alone and in combination with topical minoxidil (7). The results showed that the combination of finasteride and minoxidil generated significant augmentation of hair weight (additive effect) compared to either drug alone. Furthermore, folliculograms of scalp biopsy tissue showed a higher frequency of late anagen follicles in subjects treated with 5% minoxidil than in those administered a 2% concentration (7). Analysis of the data confirms that using minoxidil and finasteride together is significantly better than using either alone, and that minoxidil in higher concentrations is more effective than at lower concentrations.
At the 1995 American Association of Dermatology Meeting in New Orleans, results from a one year, double-blind, randomized, placebo-controlled study with finasteride in the treatment of male pattern baldness were presented. Men taking oral finasteride (5 mg/day) had significantly increased hair counts and significantly improved clinical change from baseline as assessed by multiple parameters including patient self evaluation. There were few drug related side effects reported, with similar numbers in both finasteride and placebo groups.
At the same meeting, results from a dose-range-finding study were presented, evaluating finasteride at doses of 0.01, 0.05, 0.2, 1 and 5 mg/day. A six week trial measured concentrations of scalp skin and serum dihydrotestosterone. Surprisingly, other than the group taking 0.01 mg/day, no significant differences between the doses were seen. However, significant differences were documented between the groups that received finasteride (excluding those receiving 0.01 mg/day) and the group that received placebo. It was determined that a low dose of oral finasteride will be used for further studies in the treatment of male pattern baldness.
At the annual meeting of the American Academy of Dermatology during March, 1997 in San Francisco, the Phase III clinical trials were presented for Propecia, 1 mg. finasteride. The tests evaluated 1,553 men with male pattern baldness in placebo controlled studies for one year.
According to Keith Kaufman, M.D., director of clinical research at Merck & Co., Inc., there was a 107-hair improvement in men taking Propecia (1mg finasteride) compared to those receiving placebo. Scalp hair growth was measured by counting hairs in a 1 inch diameter circle of active hair loss at the vertex. The increased hair growth achieved with 1mg finasteride was evaluated by the patients as well as by clinical investigators and by review of patient photographs by a panel of dermatologists with expertise in hair loss. By all parameters, treatment with oral daily 1mg doses of finasteride demonstrated improved hair growth. Overall improvement was seen as early as three months with continued improvement over the 24 month trial.
The 1mg daily oral doses of finasteride were generally well tolerated as side effects were reportedly uncommon. Safety was evaluated in more than 3200 men through clinical and laboratory monitoring. Ironically, discontinuation of therapy in Phase III trials due to adverse experience occurred in a higher percentage in the men on placebo (2.1%) than in the men treated with Propecia (1.7%). According to Merck, less than 2% of men experienced decreased libido. Less than 1.5% of men had difficulty achieving an erection. And, less than 1% of men complained of a decrease in the amount of semen. According to Dr. Kaufman, these side effects resolved in men who discontinued therapy with Propecia and, in fact, in many who continued therapy with Propecia. It should be noted that this data was supplied by Merck & Co., not by REGROWTH, LLC.
The concentration of dihydrotestosterone in the scalp is decreased by approximately 60% in patients taking 1mg of finasteride daily. Since finasteride inhibits a key factor responsible for miniaturization of scalp hair follicles, this allows for a reversal of the balding process.
Subsequent reports from Merck & Co., Inc. demonstrate that daily doses of 1mg finasteride is also effective at halting hair loss. Evaluation at the end of a one year study showed that only 14% of patients on Propecia lost hair, as opposed to 58% of patients on placebo. There was continued improvement in patients taking 1 mg. finasteride over 24 months.
More recent results proved that finasteride is also successful in reversing frontal hair loss, although slightly less effectively than at the vertex. This additional information is very encouraging to many patients who are disappointed in the limited ability of minoxidil to stimulate frontal hair growth. The combination therapy has been effective for most patients.
When you are getting a physical examination or are having laboratory tests on your blood, inform your doctor that you are taking finasteride. Finasteride will decrease the PSA (Prostate Specific Antigen) level by approximately 50%. Assessing the PSA level is a screening test for possible prostate cancer.
Richard Lee, M.D.
(1)Hamilton JB. Male hormone stimulation is prerequisite and incitant in common baldness. Am J Anat. 71:451-80, 1942
(2)Ebling FJG. Hair follicles and associated glands as androgen targets. Clin Endocrinol Metab. 15:319-39, 1986
(3)Bingham KD, Shaw DA. The metabolism of testosterone by human male scalp skin. J Endocrinol. 57:111-21, 1973
(4)Jenkins, Anderson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steroid 5-alpha-reductase. J Clin Invest. 89:293-300, 1992
(5)Stoner E. The clinical development of a 5-alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 37:375-378, 1990
(6)Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1185-1191, 1992
(7)Diabi AR, Mulholland MJ, Shull KL, Kubicek MF, Johnson GA, Schostarez HJ, Brunden MN and Buhl AE. Hair Growth Effects of Oral Administration of finasteride, a steroid 5-alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab. 74:345-350, 1992
INSTRUCTIONS FOR USE:
Take one tablet by mouth each day
You may take Propecia with or without food
If you forget to take Propecia, do not take an extra tablet. Just take the next tablet as usual
Propecia will not work faster or better if you take it more than once a day or if you increase the dosage.
a couple of questions
1) would 1 mg a day be sufficient?
2) how long would you want to run it after cycle?
3) when would you want to start it?
thanks........
Last edited:
